Sublingual Immunotherapy Offers Little Benefit for Grass Allergy

This article originally appeared here.
Share this content:
Sublingual Immunotherapy Offers Little Benefit for Grass Allergy
Sublingual Immunotherapy Offers Little Benefit for Grass Allergy

WEDNESDAY, July 1, 2015 (HealthDay News) -- The benefit of sublingual immunotherapy (SLIT) over placebo for seasonal grass pollen allergies is small, according to new research published online June 29 in JAMA Internal Medicine.

Gabriele Di Lorenzo, M.D., of the department of internal medicine at the University of Palermo in Italy, and colleagues looked at 25 clinical trials that evaluated the effectiveness of grass pollen sublingual tablets in reducing symptoms and the need for other allergy medications. Di Lorenzo told HealthDay that some previous trials overestimated the drugs' benefit because of the way differences between active medicine and placebo were calculated. For the new analysis, the researchers said the real difference was estimated correctly.

In the analysis, when SLIT was compared with placebo, symptom scores differed by just 1 point. Study participants could also take allergy medicine, such as antihistamines, and this is what mainly controlled symptoms, Di Lorenzo said. Adverse effects were reported by 61.3 percent of those in the SLIT group and 20.9 percent receiving placebo. Seven patients in the SLIT group reported treatment-related adverse events that required epinephrine.

"Findings show a small benefit of the grass pollen sublingual tablets in reducing symptoms and in decreasing the use of symptomatic medication (antihistamines and corticosteroids) in patients with seasonal allergic rhinoconjunctivitis," the authors write. "Considering the low magnitude of the benefit, the convenience and easy administration do not seem to be sufficient reasons for the choice of SLIT."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »